Prothena (PRTA) News Today $7.72 -0.20 (-2.53%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$7.91 +0.19 (+2.46%) As of 04:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Prothena (NASDAQ:PRTA) Receives Buy Rating from HC Wainwright3 hours ago | americanbankingnews.comRoyal Bank Of Canada Cuts Prothena (NASDAQ:PRTA) Price Target to $10.004 hours ago | americanbankingnews.comHC Wainwright Has Weak Forecast for Prothena FY2025 Earnings5 hours ago | americanbankingnews.comNovo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns HopefulAugust 7 at 2:28 AM | msn.comProthena (NASDAQ:PRTA) Price Target Cut to $10.00 by Analysts at Royal Bank Of CanadaAugust 6 at 11:07 AM | marketbeat.comProthena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with CardiomyopathyAugust 6 at 9:27 AM | businesswire.comProthena's (PRTA) Buy Rating Reiterated at HC WainwrightAugust 6 at 8:32 AM | marketbeat.comProthena (NASDAQ:PRTA) Given "Buy" Rating at Chardan CapitalAugust 6 at 8:09 AM | marketbeat.comProthena (NASDAQ:PRTA) Announces Earnings Results, Misses Expectations By $0.80 EPSAugust 5 at 6:23 PM | marketbeat.com9 Analysts Assess Prothena Corp: What You Need To KnowAugust 5 at 12:52 PM | benzinga.comProthena Reports Q2 2025 Financial Results and Pipeline ProgressAugust 4, 2025 | tipranks.comProthena Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 4, 2025 | businesswire.comProthena Corporation plc (NASDAQ:PRTA) Shares Purchased by DCF Advisers LLCAugust 4, 2025 | marketbeat.comFederated Hermes Inc. Sells 199,922 Shares of Prothena Corporation plc (NASDAQ:PRTA)August 3, 2025 | marketbeat.comA Glimpse of Prothena Corp's Earnings PotentialAugust 2, 2025 | benzinga.comProthena (PRTA) Expected to Announce Quarterly Earnings on MondayAugust 2, 2025 | americanbankingnews.comProthena Secures Leadership with New Executive AgreementsJuly 31, 2025 | msn.comProthena (PRTA) Projected to Post Earnings on MondayJuly 30, 2025 | marketbeat.comProthena to Report Second Quarter 2025 Financial Results on August 4July 28, 2025 | finance.yahoo.comProthena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Hold" from AnalystsJuly 20, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?July 12, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Passes Below 200 Day Moving Average - Should You Sell?July 4, 2025 | marketbeat.comProthena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by AnalystsJune 25, 2025 | marketbeat.comProthena Corp (PRTA) Receives Reiterated Neutral Rating from Cantor Fitzgerald | PRTA Stock NewsJune 20, 2025 | gurufocus.comCantor Fitzgerald Reiterates "Neutral" Rating for Prothena (NASDAQ:PRTA)June 20, 2025 | marketbeat.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 19, 2025 | finance.yahoo.comProthena Announces Corporate RestructuringJune 18, 2025 | finance.yahoo.comProthena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average - Time to Sell?June 18, 2025 | marketbeat.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 17, 2025 | msn.comProthena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | uk.finance.yahoo.comProthena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | businesswire.comProthena Co. plc (NASDAQ:PRTA) Short Interest Down 50.7% in MayJune 14, 2025 | marketbeat.comCantor Fitzgerald Weighs in on Prothena FY2026 EarningsJune 10, 2025 | marketbeat.comPRTA Prothena Corporation plcJune 7, 2025 | seekingalpha.comProthena Co. plc (NASDAQ:PRTA) Short Interest Up 20.1% in MayJune 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in Prothena Co. plc (NASDAQ:PRTA)June 3, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of "Hold" by BrokeragesJune 1, 2025 | marketbeat.comFY2025 EPS Estimates for Prothena Cut by Chardan CapitalMay 31, 2025 | marketbeat.comPiper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial DiscontinuationMay 30, 2025 | msn.comChardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial FailureMay 30, 2025 | msn.comH.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PTMay 30, 2025 | insidermonkey.comFY2027 EPS Estimates for Prothena Decreased by HC WainwrightMay 30, 2025 | marketbeat.comWellington Management Group LLP Increases Position in Prothena Co. plc (NASDAQ:PRTA)May 30, 2025 | marketbeat.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 30, 2025 | finance.yahoo.comB of A Securities Downgrades Prothena (PRTA)May 29, 2025 | msn.comProthena (NASDAQ:PRTA) Lowered to Underperform Rating by Bank of AmericaMay 29, 2025 | marketbeat.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 28, 2025 | finance.yahoo.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 28, 2025 | insidermonkey.comPiper Sandler Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock PriceMay 28, 2025 | marketbeat.comProthena Target of Unusually High Options Trading (NASDAQ:PRTA)May 28, 2025 | marketbeat.com Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTA Media Mentions By Week PRTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRTA News Sentiment▼0.020.39▲Average Medical News Sentiment PRTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRTA Articles This Week▼244▲PRTA Articles Average Week Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Schrodinger News Today Dyne Therapeutics News Today Evotec News Today Janux Therapeutics News Today Travere Therapeutics News Today ANI Pharmaceuticals News Today Aurinia Pharmaceuticals News Today WAVE Life Sciences News Today 89BIO News Today Vera Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRTA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.